AcadeMedia Q3 Profit Climbs as International and Adult Education Segments Drive Growth 
Nvidia CEO Jensen Huang to Join Trump’s China Visit Amid AI Chip Tensions 
Armani Group Eyes Strategic Stake Sale to Luxury Giants 
Dulles Airport Rebuild Plan Could Transform Washington’s Main International Gateway 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
K+S Raises 2026 Earnings Outlook After Strong Q1 Results 
Ibiden Stock Surges as AI Chip Demand Boosts Profit Outlook 
EQT Launches $3.76 Billion Take-Private Deal for Kakaku.com as Shares Surge 
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector 
Japan’s Top Banks to Gain Access to Anthropic’s Claude Mythos AI Model 
OpenAI-Microsoft Deal Sets $38 Billion Revenue-Sharing Cap Ahead of Potential IPO 
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
Anthropic Eyes $300M Stainless Acquisition Amid Enterprise AI Expansion 
Reliance Industries Reworks Jio IPO Into Fresh Share Sale Amid Valuation Talks 
CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
US Auto Industry Urges Trump to Block Chinese EV Market Access 
SAN ANTONIO, Texas, May 03, 2017 -- bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030.
Titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” the EPO patent for bioAffinity’s platform test for early cancer detection will significantly increase bioAffinity’s intellectual property (IP) portfolio that currently consists of 43 awarded patents in 22 countries.
bioAffinity’s porphyrin-based CyPath® bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence that is detectable and measurable by flow cytometry. CyPath® Lung, bioAffinity’s initial product, is designed to be a highly accurate, non-invasive, early-stage lung cancer diagnostic for use by patients at risk for lung cancer.
“According to the World Health Organization, nearly 30 percent of European adults are smokers, and smoking among adolescents is on the rise,” bioAffinity President and CEO Maria Zannes said. “Tobacco use causes 16 percent of all deaths in the adult population over 30 years of age. We expect our CyPath® product to have a significant positive impact on early detection of lung cancer in the European Union.”
bioAffinity is focused on the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics for multiple cancers. CyPath® Lung is a simple and cost-effective diagnostic, which will make it particularly valuable in countries with large populations and broad economic and social demographics.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747
